Gsa Capital Partners LLP Zentalis Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 608,585 shares of ZNTL stock, worth $1.06 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
608,585
Previous 255,201
138.47%
Holding current value
$1.06 Million
Previous $1.04 Million
114.56%
% of portfolio
0.17%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding ZNTL
# of Institutions
139Shares Held
67.9MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$24.3 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$14.9 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$8.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$8.03 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$5.41 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $99.2M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...